Biocon Limited (NSE: BIOCON)
India
· Delayed Price · Currency is INR | Market Cap | 386.69B |
| Revenue (ttm) | 148.94B |
| Net Income (ttm) | 14.39B |
| Shares Out | 1.20B |
| EPS (ttm) | 12.00 |
| PE Ratio | 26.92 |
| Forward PE | 45.25 |
| Dividend | 0.50 (0.15%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 764,059 |
| Open | 327.30 |
| Previous Close | 327.05 |
| Day's Range | 319.50 - 328.40 |
| 52-Week Range | 231.25 - 395.80 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
Biocon shares surge over 3% after Bengaluru facilities get VAI Tag from USFDA
Biocon Ltd. saw its shares rise by more than 3% in early trading after the U.S. Food and Drug Administration (USFDA) issued a “Voluntary Action Indicated” (VAI) tag to the manufacturing facilities of ...
Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure
In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...
Access to healthcare will remain a priority for the US, says Biocon CEO
Peter Bains, Group CEO of Biocon, talks about how the India-based pharmaceutical company is placed ahead of a second Trump presidency, as well as the development of its weight-loss and anti-obesity dr...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Stocks to watch today: L&T, Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon post Q2 results – Brokerage reports inside
Several leading companies, including Larsen & Toubro (L&T), Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon, announced their Q2 FY25 results yesterday. Here’s a look at their performance, ...
Biocon Q2 FY25 Results: Company posts net loss of Rs 16 crore, Revenue flat at Rs 3,623 crore
Biocon reported a net loss of ₹16 crore for the period, attributed to higher tax expenses resulting from a geographical shift in profits and minority interest.
Stocks to watch today as key Q2 FY24-25 results roll in: L&T, Tata Power, Dabur, PGHH, Biocon, Aditya Birla Capital and more
Today is set to be an active trading day with several prominent companies scheduled to release their Q2 FY24-25 earnings. Investors will be closely analyzing these results to gauge company performance...
HSBC on Biocon: Reduce call, sees 7.8% downside from current share price
HSBC has maintained its reduce rating on Biocon, lowering the share price target to ₹300, implying a 7.8% downside from the current market price (CMP). A positive court ruling positions Amgen well for...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Biocon’s subsidiary refinances USD 1.1 Billion long-term debt through USD bonds and new syndicated facility
Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, successfully refinanced its USD 1.1 billion (INR 93,468 million) long-term debt through the issuance of USD 800 million (INR 66,763 mill...
Stock Market 14 Feb, Today: Focus on new listings, 3 IPOs to track today
Today’s stock market highlights several companies experiencing key developments, with notable movements in IT, renewable energy, pharma, and finance sectors. Accenture’s positive revenue guidance has ...
Biocon Limited partners with Tabuk Pharmaceuticals
To commercialise its Glucagon-like peptide-1 (GLP -1) products in the Middle East region
Biocon and Tabuk Pharmaceuticals join forces to commercialize GLP-1 products in Middle East markets
Biocon Limited has recently informed exchanges that the company has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company (a fully-owned subsidiary of Astra Industria...
F&O ban update: ABFRL, IDEA enter ban; RBL Bank exits on Sept 24
In today’s stock market session, several changes were observed in the Futures and Options (F&O) ban list. New additions to the ban: ABFRL and IDEA have been placed under the F&O ban. These stocks have...
Stock market news: Aarti Industries, Biocon, GNFC, Granules India among stocks in F&O ban list on September 20
Several stocks remain in the Futures and Options (F&O) ban period as their open interest (OI) has crossed 95% of the market-wide position limits (MWPL). These stocks will remain in the ban until their...
LIC increases its stake in Biocon to 5.03%
The Life Insurance Corporation of India (LIC) has announced an increase in its equity shareholding in Biocon Ltd
Biocon Biologics set to raise $950 million through overseas bonds
Biocon Biologics is planning to raise $950 million by selling bonds overseas, according to reports of Economic Times. The fundraising will be handled by lenders including Standard Chartered Bank and H...
Who is Piyush Pratik, the IIT-graduate Apple product manager who spoke about Camera Control feature on iPhone 16 series
Apple introduced its iPhone 16 series at a launch event where Piyush Pratik highlighted the new Camera Control feature. An IIT Delhi alumnus and Stanford MBA graduate, Pratik has a notable career hist...
Biocon, ABRFL, Hindustan Copper among other stocks in F&O ban list on September 9
As of today, September 9, 2024, several stocks are under a trading ban in the futures and options (F&O) markets. This ban is enforced when the open interest on a stock reaches more than 95% of the mar...
Stocks to watch: Maruti, TVS Motors, Emami, NBCC, Biocon, Eicher Motors in focus today (Sept 2, 2024)
The Indian stock market is poised for an eventful day as several companies make headlines with significant developments. From sales figures to acquisitions and regulatory changes, here’s a quick rundo...
Biocon unit gets FDA nod for generic drug
Biocon's subsidiary has been granted approval by the US health regulator to market a generic medication for chronic heart failure treatment.
Want B’luru to be safest city in India: Mazumdar-Shaw
Bengaluru: Batting for safe cities, Kiran Mazumdar-Shaw, executive chairperson and founder of Biocon Ltd, on Saturday said safety of citizens, especia.
CEO of India's Biocon discusses first-quarter results
Peter Bains, group CEO of the biopharmaceutical company, outlines its growth outlook.
Biocon Q1 profit up 6x at 660 crore
India Business News: NEW DELHI: Biotechnology firm Biocon on Thursday said its consolidated profit after tax rose over six-fold to Rs 660 crore in the first quarter ended .
Biocon Q1 profit up 6x at 660cr
Read about Biocon's remarkable six-fold increase in Q1 profit to Rs 660 crore. Discover the reasons behind this significant growth and its impact on the biotechnology industry.